跳到正文
Relay Therapeutics· @Relay_Tx · X·· 12 天前AI 评分45
AI 导读

Relay Therapeutics公布2026年第三季度财务业绩及公司进展,ReDiscover-2 III期试验入组持续推进,现预计2027年年中完成。公司将在#ASH26公布ReInspire血管异常更新数据,并任命Shannon Campbell负责zovegalisib商业化准备,同时推进新的突变选择性TIE2项目。

正文 · 原文

Today, we report third quarter 2026 financial results and corporate updates. We saw meaningful progress in Q3: continued Phase 3 ReDiscover-2 enrollment, now estimated to complete in mid-2027, updated ReInspire vascular anomalies data coming at #ASH26, the appointment of Shannon Campbell to lead commercial preparations for zovegalisib, and a new mutant-selective TIE2 program. Read more: https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-reports-third-quarter-2026-financial-results

来源:Relay Therapeutics · x.com